As one of the most prevalent cancers, prostate cancer has enormous public health importance and its prevention seems to be a rational approach to attenuate the economic, emotional, physical, and social impact of this disease. This review discusses some of the options available to clinicians worldwide under the broad headings of chemoprevention and dietary modification including lifestyle issues. From the review of available literature, it is appreciated that although many exciting options such as androgen inhibitors, vitamin E, and selenium are being actively considered, they are far from being included in clinical practice. So until large randomized trials confirm the benefit of chemopreventives and dietary modifications, patients may be advised to pursue a diet and lifestyle that ensures overall fitness.
Adhami, V.M., Ahmad, N., & Mukhtar, H. (2003). Molecular targets for green tea in prostate cancer prevention. Journal of Nutrition, 133(7 Suppl.), 2417S-2424S.
2.
Adlercreutz, H., Markkanen, H., & Watanabe, S. (1993). Plasma concentrations of phyto-oestrogens in Japanese men. Lancet, 342(8881), 1209-1210.
3.
Albanes, D., Heinonen, O.P., Huttunen, J.K., Taylor, P.R., Virtamo, J., Edwards, B.K., et al. (1995). Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. American Journal of Clinical Nutrition, 62(6 Suppl.), 1427S-1430S.
4.
Algarte-Genin, M., Cussenot, O., & Costa, P. (2004). Prevention of prostate cancer by androgens: Experimental paradox or clinical reality. European Urology, 46(3), 285-294.
5.
Andersson, S.O., Wolk, A., Bergstrom, R., Adami, H.O., Engholm, G., Englund, A., et al. (1997). Body size and prostate cancer: A 20-year follow-up study among 135006 Swedish construction workers. Journal of the National Cancer Institute, 89(5), 385-389.
6.
Andriole, G., Bostwick, D., Brawley, O., Gomella, L., Marberger, M., Tindall, D., et al. (2004). Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. Journal of Urology, 172(4 Pt 1), 1314-1317.
7.
Badawi, A.F. (2000). The role of prostaglandin synthesis in prostate cancer. BJU International, 85(4), 451-462.
8.
Barber, N.J., Zhang, X., Zhu, G., Pramanik, R., Barber, J.A., Martin, F.L., et al. (2006). Lycopene inhibits DNA synthesis in primary prostate epithelial cells in vitro and its administration is associated with a reduced prostate-specific antigen velocity in a phase II clinical study . Prostate Cancer and Prostatic Diseases, 9(4), 407-413.
9.
Barella, L., Rota, C., Stocklin, E., & Rimbach, G. (2004). Alpha-tocopherol affects androgen metabolism in male rat. Annals of the New York Academy of Sciences, 1031, 334-336.
10.
Bartolucci, A.A., & Howard, G. (2006). Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. American Journal of Cardiology, 98(6), 746-750.
11.
Bidoli, E., Talamini, R., Bosetti, C., Negri, E., Maruzzi, D., Montella, M., et al. (2005). Macronutrients, fatty acids, cholesterol and prostate cancer risk. Annals of Oncology, 16(1), 152-157.
12.
Bjelakovic, G., Nikolova, D., Gluud, L.L., Simonetti, R.G., & Gluud, C. (2007). Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: Systematic review and meta-analysis . Journal of the American Medical Association, 297(8), 842-857.
13.
Boileau, T.W., Liao, Z., Kim, S., Lemeshow, S., Erdman, J.W., Jr., & Clinton, S.K. (2003). Prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. Journal of the National Cancer Institute, 95(21), 1578-1586.
14.
Bostwick, D.G., Qian, J., Civantos, F., Roehrborn, C.G., & Montironi, R. (2004). Does finasteride alter the pathology of the prostate and cancer grading? Clinical Prostate Cancer, 2(4), 228-235.
15.
Branca, F. (2003). Dietary phyto-oestrogens and bone health. Proceedings of the Nutrition Society, 62(4), 877-887.
16.
Calle, E.E., Rodriguez, C., Walker-Thurmond, K., & Thun, M.J. (2003). Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. New England Journal of Medicine, 348(17), 1625-1638.
17.
Cerhan, J.R., Torner, J.C., Lynch, C.F., Rubenstein, L.M., Lemke, J.H., Cohen, M.B., et al. (1997). Association of smoking, body mass, and physical activity with risk of prostate cancer in the Iowa 65+ Rural Health Study (United States). Cancer Causes and Control, 8(2), 229-238.
18.
Chan, J.M., Stampfer, M.J., Ma, J., Rimm, E.B., Willett, W.C., & Giovannucci, E.L. (1999). Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States . Cancer Epidemiology, Biomarkers and Prevention, 8(10), 893-899.
19.
Cheung, B.M., Lauder, I.J., Lau, C.P., & Kumana, C.R. (2004). Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. British Journal of Clinical Pharmacology, 57(5), 640-651.
20.
Clark, L.C., Combs, G.F., Jr., Turnbull, B.W., Slate, E.H., Chalker, D.K., Chow, J., et al. (1996). Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. Journal of the American Medical Association, 276(24), 1957-1963.
21.
Clarkson, T.B. (2002). Soy, soy phytoestrogens and cardiovascular disease . Journal of Nutrition, 132(3), 566S-569S.
22.
Combs, G.F., Jr. (2005). Current evidence and research needs to support a health claim for selenium and cancer prevention. Journal of Nutrition, 135(2), 343-347.
Cyrus-David, M.S., Weinberg, A., Thompson, T., & Kadmon, D. (2005). The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: A preliminary report. Journal of Urology, 173(6), 1923-1925.
25.
Dagnelie, P.C., Schuurman, A.G., Goldbohm, R.A., & Van den Brandt, P.A. (2004). Diet, anthropometric measures and prostate cancer risk: A review of prospective cohort and intervention studies. BJU International, 93(8), 1139-1150.
26.
Dale, K.M., Coleman, C.I., Henyan, N.N., Kluger, J., & White, C.M. (2006). Statins and cancer risk: A meta-analysis. Journal of the American Medical Association, 295(1), 74-80.
27.
Davis, J.N., Singh, B., Bhuiyan, M., & Sarkar, F.H. (1998). Genistein-induced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutrition and Cancer, 32(3), 123-131.
28.
De Marzo, A.M., Platz, E.A., Sutcliffe, S., Xu, J., Gronberg, H., Drake, C.G., et al. (2007). Inflammation in prostate carcinogenesis . Nature Reviews: Cancer, 7(4), 256-269.
29.
Debes, J.D., & Tindall, D.J. (2002). The role of androgens and the androgen receptor in prostate cancer. Cancer Letters, 187(1-2), 1-7.
30.
Demark-Wahnefried, W., Price, D.T., Polascik, T.J., Robertson, C.N., Anderson, E.E., Paulson, D.F., et al. (2001). Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: Exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features. Urology, 58(1), 47-52.
31.
Demierre, M.F., Higgins, P.D., Gruber, S.B., Hawk, E., & Lippman, S.M. (2005). Statins and cancer prevention. Nature Reviews: Cancer, 5(12), 930-942.
32.
Drake, E.N. (2006). Cancer chemoprevention: Selenium as a prooxidant, not an antioxidant. Medical Hypotheses, 67(2), 318-322.
33.
Duffield-Lillico, A.J., Dalkin, B.L., Reid, M.E., Turnbull, B.W., Slate, E.H., Jacobs, E.T., et al. (2003). Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: An analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International, 91(7), 608-612.
34.
Etminan, M., FitzGerald, J.M., Gleave, M., & Chambers, K. (2005). Intake of selenium in the prevention of prostate cancer: A systematic review and meta-analysis. Cancer Causes and Control, 16(9), 1125-1131.
35.
Fisher, B., Costantino, J.P., Wickerham, D.L., Cecchini, R.S., Cronin, W.M., Robidoux, A., et al. (2005). Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Journal of the National Cancer Institute , 97(22), 1652-1662.
36.
Gann, P.H., Hennekens, C.H., Sacks, F.M., Grodstein, F., Giovannucci, E.L., & Stampfer, M.J. (1994). Prospective study of plasma fatty acids and risk of prostate cancer. Journal of the National Cancer Institute, 86(4), 281-286.
37.
Giovannucci, E., Rimm, E.B., Liu, Y., Stampfer, M.J., & Willett, W.C. (2002). A prospective study of tomato products, lycopene, and prostate cancer risk. Journal of the National Cancer Institute , 94(5), 391-398.
38.
Giovannucci, E.L., Liu, Y., Leitzmann, M.F., Stampfer, M.J., & Willett, W.C. (2005). A prospective study of physical activity and incident and fatal prostate cancer. Archives of Internal Medicine, 165(9), 1005-1010.
39.
Goetzl, M.A., Vanveldhuizen, P.J., & Thrasher, J.B. (2007). Effects of soy phytoestrogens on the prostate. Prostate Cancer and Prostatic Diseases . Retrieved June 14, 2007, from http://www.nature.com/pcan/journal/v10/n3/full/4500953a.html
40.
Gong, Z., Neuhouser, M.L., Goodman, P.J., Albanes, D., Chi, C., Hsing, A.W., et al. (2006). Obesity, diabetes, and risk of prostate cancer: Results from the prostate cancer prevention trial. Cancer Epidemiology, Biomarkers and Prevention, 15(10), 1977-1983.
41.
Goodman, P.J., Thompson, I.M., Jr. , Tangen, C.M., Crowley, J.J., Ford, L.G., & Coltman , C.A., Jr. (2006). The prostate cancer prevention trial: Design, biases and interpretation of study results. Journal of Urology, 175(6), 2234-2242.
42.
Guo, Y., Wang, S., Hoot, D.R., & Clinton, S.K. (2007). Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones. Journal of Nutritional Biochemistry, 18(6), 408-417.
43.
Gupta, S., Srivastava, M., Ahmad, N., Bostwick, D.G., & Mukhtar, H. (2000). Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. The Prostate, 42(1), 73-78.
44.
Hsing, A.W., Tsao, L., & Devesa, S.S. (2000). International trends and patterns of prostate cancer incidence and mortality. International Journal of Cancer , 85(1), 60-67.
45.
Hufnagl, K., Parzefall, W., Marian, B., Kafer, M., Bukowska, K., Schulte-Hermann, R., et al. (2001). Role of transforming growth factor alpha and prostaglandins in preferential growth of preneoplastic rat hepatocytes . Carcinogenesis, 22(8), 1247-1256.
46.
Imamov, O., Lopatkin, N.A., & Gustafsson, J.A. (2004). Estrogen receptor beta in prostate cancer. New England Journal of Medicine, 351(26), 2773-2774.
47.
Ip, C. (1998). Lessons from basic research in selenium and cancer prevention. Journal of Nutrition, 128(11), 1845-1854.
48.
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M.J. (2007). Cancer statistics, 2007. CA: A Cancer Journal for Clinicians, 57(1), 43-66.
49.
Jian, L., Xie, L.P., Lee, A.H., & Binns, C.W. (2004). Protective effect of green tea against prostate cancer: A case-control study in southeast China. International Journal of Cancer, 108(1), 130-135.
50.
Jiang, C., Kim, K.H., Wang, Z., & Lu, J. (2004). Methyl selenium-induced vascular endothelial apoptosis is executed by caspases and principally mediated by p38 MAPK pathway. Nutrition and Cancer, 49(2), 174-183.
51.
Kiremidjian-Schumacher, L., Roy, M., Wishe, H.I., Cohen, M.W., & Stotzky, G. (1994). Supplementation with selenium and human immune cell functions. II. Effect on cytotoxic lymphocytes and natural killer cells . Biological Trace Element Research, 41(1-2), 115-127.
52.
Kirsh, V.A., Hayes, R.B., Mayne, S.T., Chatterjee, N., Subar, A.F., Dixon, L.B., et al. (2006). Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. Journal of the National Cancer Institute, 98(4), 245-254.
53.
Klein, E.A. (2004). Selenium and vitamin E cancer prevention trial . Annals of the New York Academy of Sciences, 1031, 234-241.
54.
Klotz, L. (2007). Active surveillance for favorable risk prostate cancer: Rationale, risks, and results. Urologic Oncology, 25(6), 505-509.
55.
Kolonel, L.N., Hankin, J.H., Whittemore, A.S., Wu, A.H., Gallagher, R.P., Wilkens, L.R., et al. (2000). Vegetables, fruits, legumes and prostate cancer: A multiethnic case-control study. Cancer Epidemiology, Biomarkers and Prevention, 9(8), 795-804.
56.
Kritchevsky, D. (2002). Caloric restriction and experimental carcinogenesis . Hybridoma and Hybridomics, 21(2), 147-151.
57.
Kulkarni, G.S., Al-Azab, R., Lockwood, G., Toi, A., Evans, A., Trachtenberg, J., et al. (2006). Evidence for a biopsy derived grade artifact among larger prostate glands. Journal of Urology, 175(2), 505-509.
58.
Leitzmann, M.F., Stampfer, M.J., Ma, J., Chan, J.M., Colditz, G.A., Willett, W.C., et al. (2002). Aspirin use in relation to risk of prostate cancer. Cancer Epidemiology, Biomarkers and Prevention, 11(10 Pt 1), 1108-1111.
59.
Leppala, J.M., Virtamo, J., Fogelholm, R., Huttunen, J.K., Albanes, D., Taylor, P.R., et al. (2000). Controlled trial of alpha-tocopherol and beta-carotene supplements on stroke incidence and mortality in male smokers . Arteriosclerosis, Thrombosis and Vascular Biology, 20(1), 230-235.
60.
Li, G.X., Hu, H., Jiang, C., Schuster, T., & Lu, J. (2007). Differential involvement of reactive oxygen species in apoptosis induced by two classes of selenium compounds in human prostate cancer cells. International Journal of Cancer, 120(9), 2034-2043.
61.
Li, H., Kantoff, P.W., Giovannucci, E., Leitzmann, M.F., Gaziano, J.M., Stampfer, M.J., et al. (2005). Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Research, 65(6), 2498-2504.
62.
Liu, X.H., Kirschenbaum, A., Yao, S., Lee, R., Holland, J.F., & Levine, A.C. (2000). Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. Journal of Urology , 164(3 Pt 1), 820-825.
63.
Mahmud, S., Franco, E., & Aprikian, A. (2004). Prostate cancer and use of nonsteroidal anti-inflammatory drugs: Systematic review and meta-analysis. British Journal of Cancer, 90(1), 93-99.
64.
Moore, C.K., Karikehalli, S., Nazeer, T., Fisher, H.A., Kaufman, R.P., Jr., & Mian, B.M. (2005). Prognostic significance of high grade prostatic intraepithelial neoplasia and atypical small acinar proliferation in the contemporary era. Journal of Urology, 173(1), 70-72.
65.
Morgentaler, A., & Rhoden, E.L. (2006). Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology, 68(6), 1263-1267.
66.
Moyad, M.A. (2004). Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: PartI. Urologic Oncology, 22(6), 466-471.
67.
Nelen, V. (2007). Epidemiology of prostate cancer. Recent Results in Cancer Research, 175, 1-8.
68.
Ottino, P., & Duncan, J.R. (1997). Effect of alpha-tocopherol succinate on free radical and lipid peroxidation levels in BL6 melanoma cells. Free Radical Biology and Medicine, 22(7), 1145-1151.
69.
Patel, A.V., Rodriguez, C., Jacobs, E.J., Solomon, L., Thun, M.J., & Calle, E.E. (2005). Recreational physical activity and risk of prostate cancer in a large cohort of U.S. men. Cancer Epidemiology, Biomarkers and Prevention, 14(1), 275-279.
70.
Platz, E.A., Leitzmann, M.F., Visvanathan, K., Rimm, E.B., Stampfer, M.J., Willett, W.C., et al. (2006). Statin drugs and risk of advanced prostate cancer. Journal of the National Cancer Institute, 98(24), 1819-1825.
71.
Poynter, J.N., Gruber, S.B., Higgins, P.D., Almog, R., Bonner, J.D., Rennert, H.S., et al. (2005). Statins and the risk of colorectal cancer . New England Journal of Medicine, 352(21), 2184-2192.
72.
Price, D., Stein, B., Sieber, P., Tutrone, R., Bailen, J., Goluboff, E., et al. (2006). Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: Results of a double-blind, placebo controlled, phase IIB clinical trial. Journal of Urology, 176(3), 965-970; discussion 970-961.
73.
Pruthi, R.S., Derksen, J.E., Moore, D., Carson, C.C., Grigson, G., Watkins, C., et al. (2006). Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clinical Cancer Research, 12(7 Pt 1), 2172-2177.
74.
Pugh, T.D., Oberley, T.D., & Weindruch, R. (1999). Dietary intervention at middle age: Caloric restriction but not dehydroepiandrosterone sulfate increases lifespan and lifetime cancer incidence in mice. Cancer Research, 59(7), 1642-1648.
75.
Raffoul, J.J., Wang, Y., Kucuk, O., Forman, J.D., Sarkar, F.H., & Hillman, G.G. (2006). Genistein inhibits radiation-induced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest. BMC Cancer, 6, 107.
76.
Raghow, S., Hooshdaran, M.Z., Katiyar, S., & Steiner, M.S. (2002). Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Research, 62(5), 1370-1376.
77.
Reuter, V.E. (1997). Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology, 49(3A Suppl.), 16-22.
78.
Rodriguez, C., Freedland, S.J., Deka, A., Jacobs, E.J., McCullough, M.L., Patel, A.V., et al. (2007). Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiology, Biomarkers and Prevention, 16(1), 63-69.
79.
Rodriguez, C., Patel, A.V., Calle, E.E., Jacobs, E.J., Chao, A., & Thun, M.J. (2001). Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiology, Biomarkers and Prevention, 10(4), 345-353.
80.
Schuurman, A.G., Goldbohm, R.A., Brants, H.A., & van den Brandt, P.A. (2002). A prospective cohort study on intake of retinol, vitamins C and E, and carotenoids and prostate cancer risk (Netherlands). Cancer Causes and Control, 13(6), 573-582.
81.
Schuurman, A.G., Goldbohm, R.A., Dorant, E., & van den Brandt, P.A. (2000). Anthropometry in relation to prostate cancer risk in the Netherlands Cohort Study. American Journal of Epidemiology, 151(6), 541-549.
82.
Shannon, J., Tewoderos, S., Garzotto, M., Beer, T.M., Derenick, R., Palma, A., et al. (2005). Statins and prostate cancer risk: A case-control study. American Journal of Epidemiology, 162(4), 318-325.
83.
Shiau, C.W., Huang, J.W., Wang, D.S., Weng, J.R., Yang, C.C., Lin, C.H., et al. (2006). alpha-Tocopheryl succinate induces apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 function . Journal of Biological Chemistry, 281(17), 11819-11825.
84.
Steiner, M.S., & Pound, C.R. (2003). Phase IIA clinical trial to test the efficacy and safety of Toremifene in men with high-grade prostatic intraepithelial neoplasia. Clinical Prostate Cancer, 2(1), 24-31.
85.
Stranges, S., Marshall, J.R., Natarajan, R., Donahue, R.P., Trevisan, M., Combs, G.F., et al. (2007). Effects of long-term selenium supplementation on the incidence of type 2 diabetes: A randomized trial. Annals of Internal Medicine, 147(4), 217-223.
86.
Swamy, M.V., Cooma, I., Reddy, B.S., & Rao, C.V. (2002). Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: A novel approach in developing effective chemopreventive regimens. International Journal of Oncology, 20(4), 753-759.
87.
Thompson, I.M., Chi, C., Ankerst, D.P., Goodman, P.J., Tangen, C.M., Lippman, S.M., et al. (2006). Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. Journal of the National Cancer Institute, 98(16), 1128-1133.
88.
Thompson, I.M., Goodman, P.J., Tangen, C.M., Lucia, M.S., Miller, G.J., Ford, L.G., et al. (2003). The influence of finasteride on the development of prostate cancer. New England Journal of Medicine, 349(3), 215-224.
89.
Thompson, I.M., Tangen, C.M., Goodman, P.J., Lucia, M.S., Parnes, H.L., Lippman, S.M., et al. (2007). Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. Journal of Urology, 177(5), 1749-1752.
90.
Traber, M.G., & Packer, L. (1995). Vitamin E: Beyond antioxidant function. American Journal of Clinical Nutrition, 62(6 Suppl.), 1501S-1509S.
91.
Tsubouchi, Y., Sano, H., Kawahito, Y., Mukai, S., Yamada, R., Kohno, M., et al. (2000). Inhibition of human lung cancer cell growth by the peroxisome proliferatoractivated receptor-gamma agonists through induction of apoptosis. Biochemical and Biophysical Research Communications , 270(2), 400-405.
92.
Veierod, M.B., Laake, P., & Thelle, D.S. (1997). Dietary fat intake and risk of prostate cancer: A prospective study of 25,708 Norwegian men. International Journal of Cancer, 73(5), 634-638.
93.
Wang, J., Eltoum, I.E., & Lamartiniere, C.A. (2007). Genistein chemoprevention of prostate cancer in TRAMP mice. Journal of Carcinogenesis , 6, 3.
94.
Waters, D.J., Shen, S., Cooley, D.M., Bostwick, D.G., Qian, J., Combs, G.F., Jr., et al. (2003). Effects of dietary selenium supplementation on DNA damage and apoptosis in canine prostate. Journal of the National Cancer Institute, 95(3), 237-241.
95.
Willett, W.C., Polk, B.F., Underwood, B.A., Stampfer, M.J., Pressel, S., Rosner, B., et al. (1984). Relation of serum vitamins A and E and carotenoids to the risk of cancer. New England Journal of Medicine, 310(7), 430-434.
96.
Wright, M.E., Chang, S.C., Schatzkin, A., Albanes, D., Kipnis, V., Mouw, T., et al. (2007). Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer, 109(4), 675-684.
97.
Zeliadt, S.B., Etzioni, R.D., Penson, D.F., Thompson, I.M., & Ramsey, S.D. (2005). Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. American Journal of Medicine, 118(8), 850-857.
